27.10.2021 21:52:25
|
CDC Recommends 4th Booster Covid Vaccine Dose For Immunocompromised People
(RTTNews) - The Center for Disease Control and Prevention in the U.S recently updated its Covid-19 guidelines and said that immunocompromised people in the country may require a fourth dose of the COVID-19 vaccine.
As per the revised guidelines, any person who is above 18 years and has already got two mRNA COVID-19 vaccine shots and also received an additional mRNA vaccine dose can receive the single COVID-19 booster dose, at least six months after the third mRNA vaccine dose. The vaccine can be any one of the following- Pfizer/BioNTech, Moderna or Johnson & Johnson.
The CDC said that those people who have received both vaccine shots and are slightly or highly immunocompromised, with a gap of more than 28 days since the second dose, must take an additional mRNA dose. Next, after a period of six months, the immunocompromised people must secure a single COVID-19 booster dose.
The CDC said, "In such situations, people who are moderately and severely immunocompromised may receive a total of four COVID-19 vaccine doses."
People suffering from immunocompromising conditions or those who take immunosuppressive medications or therapies are more prone to severe Covid-19. The CDC observed that it had seen reduced effect of the vaccine in immunocompromised participants than those who are not.
FDA acting commissioner Dr. Janet Woodcock said, "The availability of these authorized boosters is important for continued protection against COVID-19 disease."
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Moderna Incmehr Nachrichten
08.01.25 |
Verluste in New York: Das macht der S&P 500 aktuell (finanzen.at) | |
08.01.25 |
Aufschläge in New York: Anleger lassen S&P 500 am Mittwochmittag steigen (finanzen.at) | |
08.01.25 |
Zurückhaltung in New York: S&P 500 präsentiert sich zum Start schwächer (finanzen.at) | |
07.01.25 |
NYSE-Handel S&P 500 beendet die Dienstagssitzung in der Verlustzone (finanzen.at) | |
07.01.25 |
Schwache Performance in New York: S&P 500 gibt nach (finanzen.at) | |
07.01.25 |
Minuszeichen in New York: Das macht der S&P 500 aktuell (finanzen.at) | |
07.01.25 |
Gewinne in New York: S&P 500 zum Handelsstart mit Gewinnen (finanzen.at) | |
02.01.25 |
S&P 500-Titel Moderna-Aktie: So viel hätten Anleger an einem Moderna-Investment von vor 5 Jahren verdient (finanzen.at) |
Analysen zu Moderna Incmehr Analysen
19.11.24 | Moderna Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
13.09.24 | Moderna Underweight | JP Morgan Chase & Co. | |
05.08.24 | Moderna Sector Perform | RBC Capital Markets | |
12.01.24 | Moderna Outperform | RBC Capital Markets | |
03.11.23 | Moderna Buy | Goldman Sachs Group Inc. |
Aktien in diesem Artikel
Moderna Inc | 42,59 | 1,09% | |
Pfizer Inc. | 26,09 | 0,60% |